The role of osteoprotegerin in cardiovascular disease (Q38056541)

27 August 2017

The role of osteoprotegerin in cardiovascular disease (English)

1 reference

27 August 2017

cardiovascular disease

1 reference

2

Giuseppe Lippi

1 reference

27 August 2017

1

Martina Montagnana

1 reference

27 August 2017

Elisa Danese

3

1 reference

PubMed ID

23110639

27 August 2017

Gian Cesare Guidi

series ordinal

4

1 reference

PubMed ID

23110639

27 August 2017

language of work or name

English

0 references

publication date

30 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

45

1 reference

27 August 2017

254-264

1 reference

27 August 2017

3

1 reference

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

27 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Characterization of structural domains of human osteoclastogenesis inhibitory factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Apo2L/TRAIL and its death and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Vascular calcification: mechanisms and clinical ramifications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice--brief report.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Preclinical vascular damage in white postmenopausal women: the relevance of osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromsø Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Plasma osteoprotegerin levels and long-term prognosis in patients with intermediate coronary artery lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin gene polymorphisms in men with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Vascular calcification: pathobiological mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin concentrations and prognosis in acute ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Serum levels of osteoprotegerin increase with age in a healthy adult population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Correlates of osteoprotegerin levels in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Determinants of endothelial function in a cohort of patients with peripheral artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Endothelial dysfunction: a marker of atherosclerotic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin and diabetic macroangiopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin and mortality in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (S

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Aortic valve calcification: determinants and progression in the population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Receptor activator of nuclear factor kappa B ligand/osteoprotegerin pathway is a promising target to reduce atherosclerotic plaque calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Fully human therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Skeletal and extraskeletal actions of denosumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.727019

10.3109/07853890.2012.727019

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

23110639